Please Wait.....
Report
Global Diabetic Retinopathy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 113 Pages I Mordor Intelligence
Global Diabetic Retinopathy Market Analysis
The diabetic retinopathy market reached USD 10.08 million in 2025 and is projected to expand to USD 13.71 million by 2030, reflecting a 6.35% CAGR. Growth stems from the rising global diabetes burden, rapid uptake of AI-enabled screening, and broader therapeutic choices that now include sustained-release biologics and pipeline gene therapies. Aging populations amplify demand, with nearly 10 million patients in the United States and more than 100 million worldwide living with some form of diabetic retinopathy. North America retains leadership on the strength of advanced health systems, while Asia-Pacific shows the fastest gains as tele-ophthalmology programs scale across large diabetic populations. Competitive intensity rose sharply in 2024 when five aflibercept biosimilars entered the United States, triggering price competition and widening patient access.
Global Diabetic Retinopathy Market Trends and Insights
Rising Global Diabetes Prevalence & Earlier Screening
International Federation of Diabetes data foresee 12% of the world's adults living with diabetes by 2045, enlarging the treatable pool for the diabetic retinopathy market . Meta-analyses confirm disease rates above 22% in multiple screening programs, underlining a consistent burden across regions. AI tools that deliver 92-93% sensitivity now detect micro-aneurysms at routine primary-care visits, shifting diagnosis to earlier, more treatable stages. Chile's national tele-ophthalmology network cut specialist referrals to 15% while preserving coverage, showing scalable early detection in lower-resource settings.
Aging Population Increasing Vision-Threatening Cases
Patients with more than 10 years of diabetes carry 4.36-fold higher odds of retinopathy, and most are over 60 years old. China reports prevalence between 24.7% and 43.1%, highlighting the aging-duration nexus in the region. Female patients have shown bigger increases in blindness, suggesting the need for gender-specific care strategies. Vitrectomy demand mirrors these trends, expanding 8.14% annually as elderly patients present with complex proliferative disease.
Shortage of Retinal Specialists in Emerging Markets
The United States is projected to face a 12% fall in ophthalmologist supply versus a 24% rise in demand by 2035, and rural counties may meet only 26-29% of their staffing need . Asia-Pacific shows even sharper gaps as diabetic prevalence climbs faster than specialist training, prompting governments to fund telemedicine hubs and AI triage to extend reach. Arkansas illustrated scalable coverage using statewide teleretinal screening linked to urban retina centers, an approach now copied in Latin America and South Asia.
Other drivers and restraints analyzed in the detailed report include:
Expanding Indications & Reimbursement for Long-Acting Anti-VEGF Biologics / AI-Enabled Retinal Screening Adoption in Primary-Care Clinics / High Treatment Burden & Poor Adherence to Injection Regimens /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Non-proliferative disease accounted for 63.25% diabetic retinopathy market share in 2024, underscoring the impact of screening that now captures pathology earlier. AI systems detecting subtle micro-aneurysms push more patients into preventive care pathways rather than late-stage surgery. Proliferative cases, although smaller, will rise at 7.38% CAGR as aging and disease duration fuel advanced pathology, expanding demand for surgery and regenerative therapies.
Clinical management differs sharply. Non-proliferative patients benefit from systemic agents such as fenofibrate, which cut progression by 27% in trials. Proliferative disease increasingly involves vitrectomy, the fastest-growing modality at 8.14% CAGR. Early gene therapy data show 2-step DRSS improvement in 20% of treated non-proliferative patients, suggesting future disease-stage-specific regimens. The diabetic retinopathy market size for proliferative interventions is projected to outpace overall growth despite the segment's current smaller base.
The Report Covers Diabetic Retinopathy Market Forecast and It is Segmented by Type (Proliferative Diabetic Retinopathy, Non-Proliferative Retinopathy), Management Approach (Anti-VEGF Drug, Intraocular Steroid Injection, Laser Surgery, and Vitrectomy), End User (Hospitals, Ophthalmology Clinics, and More), and Geography. The Values are Provided in Terms of USD Million for Above Segments.
Geography Analysis
North America captured 43.35% of diabetic retinopathy market share in 2024, supported by early adoption of FDA-cleared AI devices, fast biosimilar uptake, and generous payer coverage. The region hosts 71.15% of global diabetic eye research publications from 2012-2021, reinforcing its innovation leadership. A looming 30% shortfall in ophthalmologist supply by 2035 tempers growth, particularly in rural areas, and fuels demand for tele-retina solutions.
Asia-Pacific is expected to grow at 8.25% CAGR through 2030, the highest of all regions, propelled by diabetes incidence and large population bases. China's diabetic retinopathy prevalence up to 43.1% among diabetics underscores the region's unmet need. India's plan to screen 1 billion eyes with AI-enabled handheld cameras highlights large-scale digital health adoption. Government reimbursement expansion and rising medical tourism further spur growth.
Europe demonstrates steady growth on the strength of robust universal health systems and swift biosimilar integration. Latin America leverages tele-ophthalmology, exemplified by Chile's network that detects retinopathy in 22% of screened diabetics while cutting unnecessary referrals. The Middle East and Africa remain nascent but attractive due to high diabetes prevalence in Gulf states and incremental investment in specialty care infrastructure.
List of Companies Covered in this Report:
Abbvie / Alimera Sciences / BCN Peptides / Bausch + Lomb Corp / Carl Zeiss / Roche / Glycadia Pharmaceuticals / Johnson&Johnson / Novartis / Ocuphire Pharma / Oxurion / Regeneron Pharmaceuticals / Samsung Bioepis / Viatris / Bayer / Adverum Biotechnologies / Kodiak Sciences Inc. / Annexon Biosciences / Kubota Vision Inc. / Clearside Biomedical / Aerie Pharmaceutical / Ocular Therapeutix Inc. / Regenxbio Inc. / Chengdu Kanghong Pharmaceuticals /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Global Diabetes Prevalence & Earlier Screening
4.2.2 Aging Population Increasing Vision-Threatening Cases
4.2.3 Expanding Indications & Reimbursement For Long-Acting Anti-VEGF Biologics
4.2.4 Ai-Enabled Retinal Screening Adoption In Primary Care Clinics
4.2.5 Growth Of Tele-Ophthalmology Programs In Low-Resource Regions
4.2.6 Venture Funding In Regenerative Cell & Gene Therapies For Dr
4.3 Market Restraints
4.3.1 Shortage Of Retinal Specialists In Emerging Markets
4.3.2 High Treatment Burden & Poor Adherence To Injection Regimens
4.3.3 Delayed Regulatory Pathways For First-In-Class Biosimilars
4.3.4 Limited Real-World Evidence For Novel Combination Therapies
4.4 Value / Supply-Chain Analysis
4.5 Technological Outlook
4.6 Regulatory Landscape
4.7 Porter's Five Forces
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Buyers/Consumers
4.7.3 Bargaining Power of Suppliers
4.7.4 Threat of Substitute Products
4.7.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD million)
5.1 By Type
5.1.1 Proliferative Diabetic Retinopathy
5.1.2 Non-proliferative Retinopathy
5.2 By Management Approach
5.2.1 Anti-VEGF Drug
5.2.2 Intraocular Steroid Injection
5.2.3 Laser Surgery
5.2.4 Vitrectomy
5.3 By End-user
5.3.1 Hospitals
5.3.2 Ophthalmology Clinics
5.3.3 Ambulatory Surgical Centers
5.3.4 Others
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
6.2.1 AbbVie Inc. (Allergan)
6.2.2 Alimera Sciences
6.2.3 BCN Peptides
6.2.4 Bausch + Lomb Corp
6.2.5 Carl Zeiss Meditec AG
6.2.6 F. Hoffmann-La Roche Ltd (Genentech)
6.2.7 Glycadia Pharmaceuticals
6.2.8 Johnson & Johnson Vision
6.2.9 Novartis AG
6.2.10 Ocuphire Pharma
6.2.11 Oxurion NV
6.2.12 Regeneron Pharmaceuticals Inc
6.2.13 Samsung Bioepis
6.2.14 Viatris Inc.
6.2.15 Bayer AG
6.2.16 Adverum Biotechnologies
6.2.17 Kodiak Sciences Inc.
6.2.18 Annexon Biosciences
6.2.19 Kubota Vision Inc.
6.2.20 Clearside Biomedical
6.2.21 Aerie Pharmaceuticals
6.2.22 Ocular Therapeutix Inc.
6.2.23 Regenxbio Inc.
6.2.24 Chengdu Kanghong Pharmaceuticals
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security